

**Supplementary Table 4.** Change in eGFR during the study period in each group, categorized according to eGFR and the presence or absence of albuminuria

Subject	Pemafibrate add-on		Switch from other fibrates		Control	
	Baseline	ΔChange at 52 weeks	Baseline	ΔChange at 52 weeks	Baseline	ΔChange at 52 weeks
60 mL/min/1.73 m <sup>2</sup> ≤ eGFR	79.9±15.0	-2.0 (-4.0 to 0.0)	76.9±15.6	9.1 (5.9 to 12.2) <sup>b</sup>	80.5±17.9	-1.7 (-3.3 to -0.3) <sup>a</sup>
45 ≤ eGFR < 60 mL/min/1.73 m <sup>2</sup>	53.2±4.5	-0.2 (-2.8 to 2.5)	53.5±3.3	7.7 (5.6 to 9.7) <sup>b</sup>	55.0±8.5	1.3 (-0.6 to 3.4)
eGFR < 45 mL/min/1.73 m <sup>2</sup>	35.5±6.8	-3.2 (-6.1 to -0.4)	35.9±4.9	-0.9 (-6.5 to 4.7)	36.1±7.8	1.0 (-1.0 to 3.1)
UACR < 30	70.9±18.1	-0.2 (-2.2 to 1.8)	68.7±17.2	9.3 (6.8 to 11.7) <sup>b</sup>	69.6±18.8	0.0 (-1.4 to 1.4)
30 ≤ UACR < 300	71.1±21.0	-3.1 (-5.5 to -0.7) <sup>a</sup>	68.9±20.5	7.2 (1.8 to 12.6) <sup>a</sup>	72.4±28.1	-0.6 (-2.9 to 1.7)
300 ≤ UACR	51.1±22.3	-8.7 (-12.6 to -4.8) <sup>a</sup>	52.0±22.6	-3.5 (-13.1 to 6.1)	57.7±20.9	-4.8 (-7.1 to -2.5) <sup>b</sup>

Values are presented as mean ± standard deviation or mean change (95% confidence interval).

eGFR, estimated glomerular filtration rate; UACR, urinary albumin-creatinine ratio.

<sup>a</sup>P < 0.05, <sup>b</sup>P < 0.001 vs. baseline.